drugset / Trial / NCT00253344

Lenalidomide and Docetaxel in Treating Patients With Advanced Solid Tumors

NCT00253344 ↗

NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Lenalidomide may stop the growth of tumor cells by blocking blood flow to the tumor. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving lenalidomide together with docetaxel may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of lenalidomide when given together with docetaxel in treating patients with advanced solid tumors.

Timeline

Start
2005-06
Primary completion
2008-01
Completion
2008-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Lenalidomide Other / unclassified 25 mg Oral
Background Docetaxel Small molecule 75 mg/m2 Intravenous